ISB News

Dr. Nathan Price Promoted to Professor

Dr. Nathan Price was promoted to full professor. He also serves as the associate director of ISB. March 26, 2015

Dr. Nathan Price has been promoted to full professor. He started at ISB as an associate professor in the fall of 2011. Dr. Price also serves as the associate director of ISB and co-PI of the 100K Wellness Project. Congratulations! Learn more about the Price Lab and some of his group’s publications. ISB staff gathered to toast Dr. Price on March 26, 2015:

Dr. Nitin Baliga, Director of ISB, shares a few words about Dr. Nathan Price, who has just been promoted to full professor.

Dr. Nitin Baliga, Director of ISB, shares a few words about Dr. Nathan Price, who has just been promoted to full professor.

 

Dr. Nathan Price, who has just been promoted to full professor, delivers a few words of thanks. March 26, 2015

Dr. Nathan Price, who has just been promoted to full professor, delivers a few words of thanks. March 26, 2015

Dr. Nathan Price receives applause from his mentor Dr. Lee Hood (foreground). March 26, 2015

Dr. Nathan Price receives applause from his mentor Dr. Lee Hood (foreground). March 26, 2015

From left to right: Dr. Lee Hood, Dr. Nathan Price, Dr. Nitin Baliga. March 26, 2015

From left to right: Dr. Lee Hood, Dr. Nathan Price, Dr. Nitin Baliga. March 26, 2015

Congratulations to Dr. Nathan Price, who has been promoted to full professor. March 26, 2015

Congratulations to Dr. Nathan Price, who has been promoted to full professor. March 26, 2015

Dr. Nathan Price, who was promoted for full professor, makes the first cut in his celebration cake. March 26, 2015

Dr. Nathan Price, who was promoted for full professor, makes the first cut in his celebration cake. March 26, 2015

 

 

Recent Articles

  • Co-corresponding author and ISB President Dr. Jim Heath and co-lead author Dr. Yapeng Su.

    For Cancer Cells, There Is More Than One Path to Drug Resistance

    In findings published in the journal Nature Communications, researchers show that cancer cells can take more than one path to reach a drug-resistant cell state. These findings could have promising implications for the future of cancer care.

  • ISB researchers

    Unveiling the Guerrilla Warfare Tactics of Mycobacterium Tuberculosis

    ISB researchers have unveiled new insights on how Mycobacterium tuberculosis, the pathogen that causes tuberculosis, enters and exits a dormant state in human hosts. About a quarter of the world’s population has latent TB, so these important findings will enable and accelerate the discovery of more effective TB drugs.

  • Merck and ISB Collaborate to Understand and Treat SARS-CoV-2 Infection

    Merck is collaborating with ISB and its partners to analyze blood samples and nasal swabs from Swedish Medical Center patients with SARS-CoV-2. Blood samples will be examined using proteomic, metabolomic, transcriptomics and genetic techniques to evaluate the impact of infection on different organs, and to identify potential biomarkers to predict the risk of severe disease.